LifeVantage

LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs. The company was founded in June 1988 and is headquartered in Sandy, UT.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

LifeVantage reports 7.5% revenue growth, eyes expansion into new markets

LifeVantage's Q1 2023 results reflect strong revenue growth driven by the Americas region and successful product launches. The company's LV360 initiative and new compensation plan have shown promising results. However, challenges in the Asia Pacific and Europe region need to be addressed. The fiscal 2023 outlook presents opportunities for continued growth and expansion into new markets.

LifeVantage reports revenue growth in Q2, driven by LV360 strategy

LifeVantage's Q2 saw revenue growth, improved engagement, and successful resolution of supply chain challenges. The introduction of LV360 and product innovations drove performance. Challenges in supply chain management persist, but opportunities for growth are present.

LifeVantage reports revenue growth and product innovation in Q3

LifeVantage's Q3 performance reflects revenue growth, strong financials, and product innovation, with a focus on market expansion.
While challenges exist in regional revenue declines and market uncertainties, the company's strengths in the Americas region and product launches offer growth opportunities.
Maintaining financial stability, enhancing consultant growth, and leveraging new products position LifeVantage for continued success and market leadership.
Overall, LifeVantage's strategic initiatives and financial performance indicate a resilient business model with growth potential and shareholder value.

LifeVantage reports strong Q4 earnings, unveils special dividend for shareholders

LifeVantage's Q4 2023 results reflect robust revenue growth and improved profitability, driven by strategic initiatives and product performance. The company's commitment to shareholder value through dividends and its transformation plan underscores a positive outlook for future growth. While challenges exist, opportunities in product innovation and market expansion position LifeVantage well for continued success.

LifeVantage posts robust Q1 results, eyes international growth opportunities

LifeVantage delivered a strong Q1 2024 performance with revenue growth and improved profitability, driven by successful product sales and international expansion.
Despite challenges like currency fluctuations, the company's financial stability, strategic capital allocation, and growth outlook position it well for future success.
Opportunities in product innovation, international markets, and strategic investments underscore potential avenues for continued growth and value creation for shareholders.
Investors can be optimistic about LifeVantage's trajectory, supported by its solid financial foundation and clear strategic focus on maximizing shareholder value.

LifeVantage reports strong Q2 earnings, eyes growth through product innovation

LifeVantage showcased robust financial performance with notable EBITDA growth and revenue per consultant increase, despite a slight revenue decline.
The company's focus on product innovation, market expansion, and shareholder value enhancement positions it well for future growth and competitiveness.
Strategies to address revenue challenges, capitalize on growth opportunities, and navigate market dynamics will be crucial for sustained success.

LifeVantage reports robust Q3 performance amidst revenue challenges and growth opportunities

LifeVantage demonstrated strong operational performance and profitability improvements in Q3, despite revenue challenges.
The company's focus on consultant enrollment, new product launches, and financial stability are key strengths.
While facing revenue and margin pressures, LifeVantage has opportunities to drive growth through market expansion and product optimization.
Strategic initiatives to address challenges and capitalize on opportunities will be crucial for sustained success in future quarters.

LifeVantage reports Q4 results, eyes growth with loyalty programs

LifeVantage's Q4 2024 performance showed revenue decline but improved margins and strategic initiatives.
Strengths lie in loyalty program enhancements, positive financials, and a promising outlook for fiscal 2025.
Challenges include leadership changes, revenue decline, and the need for sustained growth in active accounts.
Opportunities exist in product launches, retention strategies, and market expansion for the company's growth.
headline

LifeVantage reports robust Q1 earnings, eyes international expansion for growth

LifeVantage's Q1 2025 showcased strong profitability despite revenue decline, driven by the successful MindBody GLP-1 System launch.
Guidance for fiscal 2025 indicates a positive outlook with revenue and EBITDA projections, supported by plans for international product expansion.
While facing revenue challenges, the company's focus on innovation, market demand, and strategic growth initiatives present opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.

SALT LAKE CITY, Jan. 16, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes, today announced that it will release financial results for its second quarter ended December 31, 2023, after the stock market closes on Tuesday, January 30, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce Second Quarter Fiscal Year 2024 Results on January 30, 2024

Hundreds of Independent Consultants host virtual watch parties to jumpstart 2024 Hundreds of Independent Consultants host virtual watch parties to jumpstart 2024

LifeVantage Hosts Global Kickoff Announcing “Rise ERA” Theme, New Sales Incentives and Global Expansion Dates for LV360

SALT LAKE CITY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announced that Steve Fife, CEO, and Carl Aure, CFO, will be participating in the Water Tower Research Fireside Chat Series on Thursday, December 14, 2023, at 11:00 am ET. This event is open access for all investors to participate.

LifeVantage Corporation to Participate in Water Tower Fireside Chat Series

Consumer Experience Leads to Scientific Investigation on Cellular Health Impact When Products are Taken Together Consumer Experience Leads to Scientific Investigation on Cellular Health Impact When Products are Taken Together

LifeVantage® Study Reveals Synergistic Effects of Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen

SALT LAKE CITY, Nov. 27, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today announced that the Board of Directors has appointed Raymond Greer as Chairman of the Board. He succeeds Garry Mauro, who will continue to serve as a member of the Board of Directors.

LifeVantage Appoints Raymond Greer as Chairman of the Board of Directors

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of LifeVantage Corporation (Nasdaq: LFVN) concerning the Company and its directors' and officers' possible violations of state laws. If you own LifeVantage Corporation stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York,.

Glancy Prongay & Murray LLP Announces Investigation of LifeVantage Corporation (LFVN)

SALT LAKE CITY, Nov. 13, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today announced the final, certified results of its fiscal year 2024 annual meeting of stockholders (the “Annual Meeting”), as provided to the Company by the independent inspector of elections. The results confirm that stockholders re-elected all seven of the Company's incumbent directors.

Stockholders Re-Elect All Seven LifeVantage Incumbent Directors at Fiscal Year 2024 Annual Meeting

LifeVantage Corporation (NASDAQ:LFVN ) Q1 2024 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - President & Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Doug Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.

LifeVantage Corporation (LFVN) Q1 2024 Earnings Call Transcript

Latest skincare innovation is the perfect addition to the internal activation benefits of Protandim ® Nrf2 Synergizer ® and TrueScience ® Liquid Collagen.

LifeVantage® Introduces TrueScience® TrueRenew Daily Firming Complex, A Better-than-Cosmetic Retinol Alternative

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group,” “we” or our “Group”), represent the largest stockholder of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), collectively owning approximately 12.8% of the Company's outstanding stock. Today, the Group issued the following letter to LifeVantage stockholders ahead of the Company's upcoming Annual Meeting of Stockholders (the “Annual Meeting.

The Radoff-Sudbury Group Reiterates the Need to Elect Directors with Governance, Turnaround and Wellness Industry Experience to LifeVantage's Board of Directors

Reminds Stockholders to Vote the WHITE Proxy Card to Ensure Continued Progress Reminds Stockholders to Vote the WHITE Proxy Card to Ensure Continued Progress

LifeVantage President and CEO Steve Fife Sends Letter to Stockholders

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group,” “we” or our “Group”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has joined Institutional Shareholder Services Inc. (“ISS”) in recommending that the Company.

Glass Lewis Joins ISS in Recommending LifeVantage Corporation's Stockholders Vote FOR Boardroom Change on the BLUE Proxy Card at the Upcoming Annual Meeting

SALT LAKE CITY, Oct. 26, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announced that it will release financial results for its first quarter ended September 30, 2023, after the stock market closes on Thursday, November 9, 2023. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce First Quarter Fiscal Year 2024 Results on November 9, 2023

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group,” “we” or our “Group”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended stockholders support boardroom change by voting on the Radoff-Sudbury G.

ISS Recommends LifeVantage Corporation's Stockholders Vote FOR Boardroom Change on the Radoff-Sudbury Group's BLUE Proxy Card at the Upcoming Annual Meeting

SALT LAKE CITY, Oct. 25, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today issued the following statement in response to a press release issued by Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with the other participants in their solicitation, the “Radoff-Sudbury Group”):

LifeVantage Responds to Radoff-Sudbury Group's False Allegations

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group,” “we” or our “Group”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today issued the below statement in response to apparent pay-for-play tactics being employed by LifeVantage's Board of Directors (the “Board”) to mislead the Company's stockholders and other key stake.

The Radoff-Sudbury Group Exposes LifeVantage Corporation's Latest Attempts to Mislead Stockholders Ahead of Annual Meeting

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group,” “we” or our “Group”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today responded to the misrepresentations and distortions included in the Company's recently issued presentation. Dayton Judd, Michael Lohner and Bradley L. Radoff have been nominated by the Radoff-Su.

The Radoff-Sudbury Group Sets the Record Straight and Highlights Key Facts that Reinforce the Need for Targeted Boardroom Change at LifeVantage Corporation

Urges Stockholders to Vote “FOR” LifeVantage's Seven Highly Engaged Directors on the WHITE Universal Proxy Card to Ensure Continued Progress Urges Stockholders to Vote “FOR” LifeVantage's Seven Highly Engaged Directors on the WHITE Universal Proxy Card to Ensure Continued Progress

LifeVantage Sends Letter and Stock Chart to Stockholders Highlighting Stock Outperformance in 2023

Highlights Decisive Actions Taken by Board to Rebuild Senior Leadership Team and Develop New LV360 Strategy That Is Delivering Results

LifeVantage Sends Letter to Stockholders and Releases Investor Presentation Detailing Success of Ongoing Transformation

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group” or “we”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today issued a presentation detailing why the Radoff-Sudbury Group believes that LifeVantage is in urgent need of new perspectives in the boardroom following years of poor performance and governance under long-ten.

The Radoff-Sudbury Group Issues Presentation Highlighting the Urgent Need for Targeted Boardroom Change at LifeVantage Corporation

Convention hosted in San Antonio, TX, October 5-7, attended by over 2,000 Independent Consultants from around the world Convention hosted in San Antonio, TX, October 5-7, attended by over 2,000 Independent Consultants from around the world

LifeVantage “All In” Global Convention 2023 Showcases Next Phases of LV360, Consultant Training, Product Reveals, New Sales Incentives, and More

Send Letter to Stockholders Detailing the Value Delivered by the Targeted Directors Send Letter to Stockholders Detailing the Value Delivered by the Targeted Directors

LifeVantage Directors Who Are Not Targeted by Dissident Stockholder Encourage LifeVantage Stockholders to Vote for All of the Board's Director Candidates

NEW YORK--(BUSINESS WIRE)--Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the “Radoff-Sudbury Group” or “we”), who collectively own approximately 12.8% of the outstanding stock of LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), today announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with LifeVantage's fiscal 2024 Annual Meeting of Stockholders (the “Annu.

The Radoff-Sudbury Group Files Definitive Proxy and Issues Letter to LifeVantage Corporation Stockholders

Issues Letter to Stockholders Highlighting the Company's Transformation and Progress with LV360 Plan

LifeVantage Files Definitive Proxy Statement

SALT LAKE CITY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023 in New York, NY.

News for LifeVantage Stock (LFVN)